Talk Bio

Actionable Insights Powered by AI

Subscribe

Biogen CEO

Braveheart Bio Launches with $185 Million Series A, Appoints Biogen CEO Christopher Viehbacher as Chair

talkbio0Tagged , , , , , , , , ,

Braveheart Bio; Series A financing; hypertrophic cardiomyopathy; Christopher Viehbacher; Biogen CEO; cardiovascular drug development; BHB-1893; myosin inhibitor; Andreessen Horowitz; Forbion; OrbiMed

Read More